RealFeedApp NRG Therapeutics launches PET imaging trial NRG5051-102
NRG Therapeutics has initiated a PET imaging biodistribution trial of its lead asset NRG5051 in healthy volunteers in London to assess central nervous system penetration. The study aims to determine blood plasma kinetics and calculate a distribution coefficient to estimate NRG5051 levels in brain parenchyma.
- Field
- the brain and neuroscience
- What they did
- NRG Therapeutics has started a clinical trial using PET imaging to track the distribution of its drug NRG5051 in healthy volunteers. The study aims to measure how deeply the drug penetrates the brain and calculate its concentration in brain tissue.
- Why it matters
- This information will help determine the correct dosage for future trials in patients with neurodegenerative diseases, such as amyotrophic lateral sclerosis.
#neurodegenerative#pet imaging#nrg5051#mitochondrial permeability transition pore#clinical trial
